Inactive Instrument

Principia Biopharma Inc.

Equities

PRNB

US74257L1089

Biotechnology & Medical Research

Principia Biopharma Appoints Shao-Lee Lin to Board of Directors

April 18, 2019 at 04:01 pm EDT

Principia Biopharma Inc. announced the appointment of Shao-Lee Lin to its Board of Directors. Dr. Lin is currently Executive Vice President, head of Research and Development and Chief Scientific Officer of Horizon Pharma plc., with past corporate experiences at AbbVie Inc., Gilead Sciences Inc., and Amgen Inc.

Latest news about Principia Biopharma Inc.

Goodwin : Sanofi buys Kymab for up to $1.5 billion to expand in immunotherapy	21-01-11	RE
Principia Biopharma Inc. Completes Patient Enrollment into the Global Phase 3 PEGASUS Trial for Rilzabrutinib	20-11-24	CI
Kiadis Pharma N : Healthcare group Sanofi offers to buy smaller peer Kiadis for 308 mln euros	20-11-02	RE
GLOBAL MARKETS LIVE: Google wins Fitbit, Epic Games loses first court battle against Apple…	20-09-29
Principia Biopharma Inc. Provides Information to Shareholders.	20-09-28	CI
Principia Biopharma Inc. Announces Executive Resignations	20-09-28	CI
Principia Biopharma Inc.(NasdaqGS:PRNB) dropped from S&P TMI Index	20-09-28	CI
Principia Biopharma Inc.(NasdaqGS:PRNB) dropped from S&P Biotechnology Select Industry Index	20-09-28	CI
Principia Biopharma Inc.(NasdaqGS:PRNB) dropped from S&P Global BMI Index	20-09-28	CI
Principia Biopharma Inc.(NasdaqGM:PRNB) dropped from Russell 2000 Value-Dynamic Index	20-09-28	CI
Principia Biopharma Inc.(NasdaqGM:PRNB) dropped from Russell 2500 Growth-Dynamic Index	20-09-28	CI
Principia Biopharma Inc.(NasdaqGM:PRNB) dropped from Russell 2500 Value-Dynamic Index	20-09-28	CI
Principia Biopharma Inc.(NasdaqGM:PRNB) dropped from Russell 3000 Index	20-09-28	CI
Principia Biopharma Inc.(NasdaqGM:PRNB) dropped from Russell 2000 Growth Index	20-09-28	CI
Principia Biopharma Inc.(NasdaqGM:PRNB) dropped from Russell 2000 Value Index	20-09-28	CI
Principia Biopharma Inc.(NasdaqGM:PRNB) dropped from Russell Small Cap Completeness Index	20-09-28	CI
Principia Biopharma Inc.(NasdaqGM:PRNB) dropped from Russell 2500 Value Index	20-09-28	CI
Principia Biopharma Inc.(NasdaqGM:PRNB) dropped from Russell 2500 Index	20-09-28	CI
Principia Biopharma Inc.(NasdaqGM:PRNB) dropped from Russell 2000 Index	20-09-28	CI
Principia Biopharma Inc.(NasdaqGM:PRNB) dropped from Russell 3000 Value Index	20-09-28	CI
Principia Biopharma Inc.(NasdaqGM:PRNB) dropped from Russell Small Cap Comp Growth Index	20-09-28	CI
Principia Biopharma Inc.(NasdaqGM:PRNB) dropped from Russell Small Cap Comp Value Index	20-09-28	CI
Principia Biopharma Inc.(NasdaqGM:PRNB) dropped from Russell 2500 Growth Index	20-09-28	CI
Principia Biopharma Inc.(NasdaqGM:PRNB) dropped from Russell 3000 Growth Index	20-09-28	CI
Principia Biopharma Inc.(NasdaqGM:PRNB) dropped from Russell 2000 Growth-Dynamic Index	20-09-28	CI

Chart Principia Biopharma Inc.

Duration

Period

More charts

Company Profile

Principia Biopharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing oral therapies to patients with unmet medical needs in immunology and oncology. It uses its Tailored Covalency platform to design and develop reversible covalent and irreversible covalent, small molecule inhibitors. Its pipeline includes PRN1008, PRN1371 and PRN2246. PRN1008 drug candidate is designed for the treatment of chronic immunological disorders. PRN2246 is an irreversible covalent BTK inhibitor for the treatment of multiple sclerosis (MS), and other central nervous system (CNS) diseases. PRN1008 is also being developed for the treatment of multiple autoimmune diseases, such as pemphigus. PRN1371 is an inhibitor of Fibroblast Growth Factor Receptor (FGFR), designed for the treatment of solid tumors. The Company also focuses on developing oral immunoproteasome inhibitor for the treatment of inflammation and autoimmune disorders.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+7.52%	113B
REGENERON PHARMACEUTICALS, INC.	+11.38%	106B
ARGENX SE	+0.96%	22.27B
BIONTECH SE	-12.64%	22.22B
GENMAB A/S	-4.64%	19.43B
WUXI APPTEC CO., LTD.	-37.85%	17.87B
BEIGENE, LTD.	-8.58%	17.24B
NEUROCRINE BIOSCIENCES, INC.	+7.77%	14.29B
SAREPTA THERAPEUTICS, INC.	+37.41%	12.52B

Bio Therapeutic Drugs